التفاصيل البيبلوغرافية
| العنوان: |
The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study. |
| المؤلفون: |
Webb, Edward J D, Howdon, Daniel, Bestwick, Rebecca, King, Natalie, Sandoe, Jonathan A T, Euden, Joanne, Grozeva, Detelina, West, Robert, Howard, Philip, Powell, Neil, Albur, Mahableshwar, Bond, Stuart, Brookes-Howell, Lucy, Dark, Paul, Hellyer, Thomas, Llewelyn, Martin, McCullagh, Iain J, Ogden, Margaret, Pallmann, Philip, Parsons, Helena |
| المصدر: |
Journal of Antimicrobial Chemotherapy (JAC); Aug2024, Vol. 79 Issue 8, p1831-1842, 12p |
| مصطلحات موضوعية: |
COVID-19 pandemic, COVID-19, QUALITY-adjusted life years, COST estimates, HEALTH boards |
| مستخلص: |
Background Many hospitals introduced procalcitonin (PCT) testing to help diagnose bacterial coinfection in individuals with COVID-19, and guide antibiotic decision-making during the COVID-19 pandemic in the UK. Objectives Evaluating cost-effectiveness of using PCT to guide antibiotic decisions in individuals hospitalized with COVID-19, as part of a wider research programme. Methods Retrospective individual-level data on patients hospitalized with COVID-19 were collected from 11 NHS acute hospital Trusts and Health Boards from England and Wales, which varied in their use of baseline PCT testing during the first COVID-19 pandemic wave. A matched analysis (part of a wider analysis reported elsewhere) created groups of patients whose PCT was/was not tested at baseline. A model was created with combined decision tree/Markov phases, parameterized with quality-of-life/unit cost estimates from the literature, and used to estimate costs and quality-adjusted life years (QALYs). Cost-effectiveness was judged at a £20 000/QALY threshold. Uncertainty was characterized using bootstrapping. Results People who had baseline PCT testing had shorter general ward/ICU stays and spent less time on antibiotics, though with overlap between the groups' 95% CIs. Those with baseline PCT testing accrued more QALYs (8.76 versus 8.62) and lower costs (£9830 versus £10 700). The point estimate was baseline PCT testing being dominant over no baseline testing, though with uncertainty: the probability of cost-effectiveness was 0.579 with a 1 year horizon and 0.872 with a lifetime horizon. Conclusions Using PCT to guide antibiotic therapy in individuals hospitalized with COVID-19 is more likely to be cost-effective than not, albeit with uncertainty. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Antimicrobial Chemotherapy (JAC) is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder